Evidence map›Paper›PMID 25230936›Full record

ArticleClinical and vaccine immunology : CVI2014

Determination of specific antibody responses to the six species of ebola and Marburg viruses by multiplexed protein microarrays.

Teddy Kamata, Mohan Natesan, Kelly Warfield, M Javad Aman, Robert G Ulrich

Open access · diamondAbstract read
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Ebolavirus comparative genomics.FEMS microbiology reviews · 2015
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Teddy KamataUnited States Army Medical Research Institute for Infectious Diseases, Frederick, Maryland, USA.
Mohan NatesanUnited States Army Medical Research Institute for Infectious Diseases, Frederick, Maryland, USA.
Kelly WarfieldIntegrated BioTherapeutics, Inc., Gaithersburg, Maryland, USA.
M Javad AmanIntegrated BioTherapeutics, Inc., Gaithersburg, Maryland, USA.
Robert G UlrichUnited States Army Medical Research Institute for Infectious Diseases, Frederick, Maryland, USA rulrich@bhsai.org.
United States Army Medical Research Institute of Infectious Diseases · USIntegrated BioTherapeutics (United States) · US

Funding

Integrated polymer microfluidic device for multiplex diagnosis of viral infectionR01AI096215 · NIAID · GENEVA FOUNDATION · PI ULRICH, ROBERT G. · 2011 to 2015
$4.4M
NIAID NIH HHS R01 AI096215NIAID NIH HHS R01AI096215
6 · The paper itself

Abstract

Infectious hemorrhagic fevers caused by the Marburg and Ebola filoviruses result in human mortality rates of up to 90%, and there are no effective vaccines or therapeutics available for clinical use. The highly infectious and lethal nature of these viruses highlights the need for reliable and sensitive diagnostic methods. We assembled a protein microarray displaying nucleoprotein (NP), virion protein 40 (VP40), and glycoprotein (GP) antigens from isolates representing the six species of filoviruses for use as a surveillance and diagnostic platform. Using the microarrays, we examined serum antibody responses of rhesus macaques vaccinated with trivalent (GP, NP, and VP40) virus-like particles (VLP) prior to infection with the Marburg virus (MARV) (i.e., Marburg marburgvirus) or the Zaire virus (ZEBOV) (i.e., Zaire ebolavirus). The microarray-based assay detected a significant increase in antigen-specific IgG resulting from immunization, while a greater level of antibody responses resulted from challenge of the vaccinated animals with ZEBOV or MARV. Further, while antibody cross-reactivities were observed among NPs and VP40s of Ebola viruses, antibody recognition of GPs was very specific. The performance of mucin-like domain fragments of GP (GP mucin) expressed in Escherichia coli was compared to that of GP ectodomains produced in eukaryotic cells. Based on results with ZEBOV and MARV proteins, antibody recognition of GP mucins that were deficient in posttranslational modifications was comparable to that of the eukaryotic cell-expressed GP ectodomains in assay performance. We conclude that the described protein microarray may translate into a sensitive assay for diagnosis and serological surveillance of infections caused by multiple species of filoviruses.

Indexed as

AnimalsAntibodies, ViralAntibody SpecificityEbola VaccinesEbolavirusHemorrhagic Fever, EbolaMacaca mulattaMarburgvirusMarburg Virus DiseaseProtein Array AnalysisViral ProteinsAntibodies, ViralEbola VaccinesViral Proteins

Identifiers

PMID25230936
PMCPMC4248775
OpenAlexW2096653831

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.